Shilpa Medicare lunches pemetrexed injection in India under the brand name VRTU
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
Positive opinions based on significant survival benefit
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Subscribe To Our Newsletter & Stay Updated